BPDF collaborates with National Strategic Research Initiative to support the development and production of defense-related biotherapeutics
With scientific breakthroughs, there is often a "eureka" moment when a researcher first realizes a process or technology can solve a problem. It’s no different with breakthroughs supporting the safety and well-being of warfighters.
BPDF Producing Protein Therapeutic for Coronavirus Patients
Working with a preclinical drug discovery company using its proprietary genetic technology platform, the BPDF is in early-stage production of a recombinant protein as a potential biotherapeutic for COVID-19 patients who may have few options for treatment.
The Biological Process Development Facility (BPDF) at the University of Nebraska offers biopharmaceutical process development and biomanufacturing services that transition discoveries to non-clinical studies and Phase I/II and early Phase III clinical trials. BPDF capabilities include:
- Master and working cell banks
- Upstream and downstream process development
- Stability testing services
- Analytical method development and qualification
- Microbial manufacture of biologics
Fermentation processes focus on optimizing and controlling high cell-density fermentations of Pichia pastoris, Saccharomyces cerevisiae, and Escherichia coli for recombinant protein production. Activities are governed by a rigorous quality system as well as regulatory support.
The BPDF has produced a wide range of biologics—including vaccines, recombinant proteins, gene therapies and other biotherapeutics—in partnership with government agencies, biotechnology companies, academic researchers, and non-profit organizations. The BPDF applies decades of expertise and experience to developing scalable and reproducible cGMP manufacturing processes.
